Doximity, Inc. Q2 2027 Earnings Recap

Doximity’s shares fell 2.0% after earnings, a roughly flat reaction. Revenue and adjusted EBITDA margin were above the company’s guidance range, while workflow-prescriber growth accelerated and AI adoption expanded; the available transcript does not provide the full outlook or enough evidence to identify a specific disappointment.

Key Takeaways

• Q2 revenue was $175 million, up 4% year over year and 2 percentage points above the high end of guidance.
• Adjusted EBITDA was $89 million, with a 51% margin—9 percentage points above the high end of guidance—even as AI spending grew more than 6x year over year.
• Quarterly active workflow prescribers grew 34% year over year to a record, reaching approximately half of the 1.8 million U.S. prescribers.
• The health-system AI client base topped 190, up from 165 the prior quarter; 10 of the nation’s top 20 hospitals were clients.
• Pharma AI search had been purchased by 16 of the top 20 pharma companies, with three more in contracting.